Anti-Hu CD3, OKT3, UC, 100??g and 4 more items

The University of Virginia awarded a contract to StemCell Technologies Inc. on August 8, 2026, under purchase order A207_PO-0273299-V3 with a cumulative contract value of $1,035.00. The contract encompasses the procurement of specialized immunological and cell culture reagents, including Anti-Human CD3 monoclonal antibody (OKT3 clone, 100 micrograms per vial) in a quantity of 145 vials, Human Peripheral Blood Mononuclear Cells (fresh, 100 million cells per vial) in a quantity of 524 vials, and ImmunoCult Human CD3/CD28/CD2 T Cell Activator (2 milliliter formulation) in a quantity of 169 vials. The contract was executed in Virginia and represents a purchase order-based award mechanism.

The contract further includes the supply of ImmunoCult-XF T Cell Expansion Medium (500 milliliter formulation) in a quantity of 195 vials, as well as associated shipping and handling services. These products are specialized reagents and cellular materials commonly utilized in immunological research, cellular therapy development, and T cell expansion protocols. All line items are being delivered to the University of Virginia as the buyer and contracting organization. The contract represents a straightforward procurement of research-grade biological materials and associated logistics services.